ITRI-501, an anti-TIGIT monoclonal antibody for solid tumor therapy

Exhibitor: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Booth No: R529

Characteristic

In solid tumor microenvironment, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is an immune checkpoint receptor that is over-expressed on regulatory T cells, activated T, and NK cells, which can inhibit anticancer immune responses. ITRI has generated a humanized and Fc effector function enhanced anti-TIGIT antibody drug candidate, ITRI-501, against TIGIT that blocks poliovirus receptor (PVR/CD155) ligand binding and inhibits TIGIT signaling. ITRI-501 exhibits the strongest ADCC activity than the benchmark antibodies. In human TIGIT gene knock-in mouse syngeneic model, ITRI-501 alone is highly potent in inhibiting MC38 tumor cell growth. Cell line development and lab-scale process and formulation have been completed with manufacturability. PK and ADA method developments have been completed.